贝瓦西祖马布生物类似药与原始者贝瓦西祖马布转移性结直肠癌的成本效益分析:使用真实世界的数据进行的一项比较研究
Brandon Lu1, Erind Dvorani2, Lena Nguyen2
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
概括
像MVASI和Zirabev这样的贝瓦西祖马布生物仿制药在转移性结直肠癌治疗中为现实世界提供了显著的成本节省. 这些生物类似药物为原始者提供了可比的生存益处,支持医疗保健的可持续性.
科学领域:
- 在瘤学瘤学.
- 药物经济学 药物经济学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 转移性结肠直肠癌 (mCRC) 的治疗通常涉及贝瓦西祖马布.
- 包括MVASI和Zirabev在内的Bevacizumab生物类似药已被批准用于一线mCRC治疗.
- 这些生物仿制药的实际成本节约和成本效益需要评估.
研究的目的:
- 量化贝瓦西祖马布生物类似药 (MVASI,Zirabev) 与原始贝瓦西祖马布相比的实际成本节约.
- 评估贝瓦西祖马布生物类似药在治疗mCRC的成本效益.
- 从公共付款人的角度评估生存效益和经济影响.
主要方法:
- 一项基于人口的回顾性队列研究在加拿大安大略省.
- 在接受原始或生物类似贝瓦齐祖马布治疗mCRC的患者中,倾向性得分匹配 (1:4) .
- 从公共支付者的角度计算1年的患者水平成本,寿命年 (LY) 和经质量调整的LY.
主要成果:
- 贝瓦西祖马布生物仿制药为每名患者节省了6379美元的成本.
- 在获得的生命年数 (0.0 LY) 或获得的质量调整的 LY (-0.01 QALY) 中没有发现显著差异.
- 增量净货币收益为6331美元,增量净健康收益为0.127 LY,在50,000美元/LY的门上,这表明了成本效益.
结论:
- 贝瓦西祖马布生物仿制药在mCRC治疗中显著节省了实际成本.
- 这些生物仿制药的生存益处与原始药物贝瓦西祖马布的生存益处相当.
- 这些发现支持实施bevacizumab生物类似药,以促进卫生系统的可持续性.
更多相关视频
09:24Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells
Published on: September 18, 2019
9.9K
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
10.8K
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
01:13Bioequivalence studies: Biowaivers
430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430